OBJECTIVE: To assess the outcome in severely ill patients with hematological malignancies who receive intravenous chemotherapy in an intensive care unit (ICU) for a life-threatening malignancy-related complication. DESIGN: Retrospective observational study of prospectively collected data. PATIENTS: All 37 critically ill patients with hematological malignancies who received intravenous chemotherapy in the ICU between January 1997 and March 2005 (mean age 46+/-19 years; mean APACHE II 23+/-7). MEASUREMENTS AND RESULTS: Thirty-seven (69%) patients received chemotherapy because of extensive disease with organ involvement (54%), extensive disease without organ involvement (19%), severe disseminated intravascular coagulation (11%), and other reasons (16%). In 41% there was concomitant infection when chemotherapy was initiated, in 86% a high-grade malignancy, and 30% relapsing disease. Twenty-three (62%) patients received mechanical ventilation at the moment of or soon after initiation of chemotherapy for a median duration of 5 days (1-67), and 24% underwent renal replacement therapy during ICU stay. Only ventilation was associated with in-hospital mortality (odds ratio 9.3). ICU, in-hospital, and 6-month mortality rates in nonventilated vs. ventilated patients were 7% and 48%, 14% and 61%, and 54% and 74%, respectively. CONCLUSIONS: Starting chemotherapy in the ICU for a life-threatening malignancy related complication can be lifesaving even when infection or organ failure is present.
OBJECTIVE: To assess the outcome in severely ill patients with hematological malignancies who receive intravenous chemotherapy in an intensive care unit (ICU) for a life-threatening malignancy-related complication. DESIGN: Retrospective observational study of prospectively collected data. PATIENTS: All 37 critically illpatients with hematological malignancies who received intravenous chemotherapy in the ICU between January 1997 and March 2005 (mean age 46+/-19 years; mean APACHE II 23+/-7). MEASUREMENTS AND RESULTS: Thirty-seven (69%) patients received chemotherapy because of extensive disease with organ involvement (54%), extensive disease without organ involvement (19%), severe disseminated intravascular coagulation (11%), and other reasons (16%). In 41% there was concomitant infection when chemotherapy was initiated, in 86% a high-grade malignancy, and 30% relapsing disease. Twenty-three (62%) patients received mechanical ventilation at the moment of or soon after initiation of chemotherapy for a median duration of 5 days (1-67), and 24% underwent renal replacement therapy during ICU stay. Only ventilation was associated with in-hospital mortality (odds ratio 9.3). ICU, in-hospital, and 6-month mortality rates in nonventilated vs. ventilated patients were 7% and 48%, 14% and 61%, and 54% and 74%, respectively. CONCLUSIONS: Starting chemotherapy in the ICU for a life-threatening malignancy related complication can be lifesaving even when infection or organ failure is present.
Authors: E Azoulay ; C Alberti ; C Bornstain ; G Leleu ; D Moreau ; C Recher ; S Chevret ; J R Le Gall ; L Brochard; B Schlemmer Journal: Crit Care Med Date: 2001-03 Impact factor: 7.598
Authors: Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay Journal: Intensive Care Med Date: 2003-03-28 Impact factor: 17.440
Authors: Dominique D Benoit; Eric A Hoste; Pieter O Depuydt; Fritz C Offner; Norbert H Lameire; Koenraad H Vandewoude; Annemieke W Dhondt; Lucien A Noens; Johan M Decruyenaere Journal: Nephrol Dial Transplant Date: 2005-01-25 Impact factor: 5.992
Authors: Pieter O Depuydt; Dominique D Benoit; Koenraad H Vandewoude; Johan M Decruyenaere; Francis A Colardyn Journal: Chest Date: 2004-10 Impact factor: 9.410
Authors: Dominique D Benoit; Koenraad H Vandewoude; Johan M Decruyenaere; Eric A Hoste; Francis A Colardyn Journal: Crit Care Med Date: 2003-01 Impact factor: 7.598
Authors: Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Daniel De Backer; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Duncan Macrae; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerôme Pugin; Michael Pinsky; Peter Radermacher; Christian Richard Journal: Intensive Care Med Date: 2007-02-14 Impact factor: 17.440
Authors: Jae-Uk Song; Gee Young Suh; Hye Yun Park; So Yeon Lim; Seo Goo Han; Yeh Rim Kang; O Jung Kwon; Sookyoung Woo; Kyeongman Jeon Journal: Intensive Care Med Date: 2012-05-17 Impact factor: 17.440
Authors: Robin H Johns; Tomas Doyle; Marc C Lipman; Kate Cwynarski; Joanne R Cleverley; Peter G Isaacson; Steve Shaw; Banwari Agarwal Journal: J Med Case Rep Date: 2010-01-30
Authors: Elie Azoulay; Peter Schellongowski; Michael Darmon; Philippe R Bauer; Dominique Benoit; Pieter Depuydt; Jigeeshu V Divatia; Virginie Lemiale; Maarten van Vliet; Anne-Pascale Meert; Djamel Mokart; Stephen M Pastores; Anders Perner; Frédéric Pène; Peter Pickkers; Kathryn A Puxty; Francois Vincent; Jorge Salluh; Ayman O Soubani; Massimo Antonelli; Thomas Staudinger; Michael von Bergwelt-Baildon; Marcio Soares Journal: Intensive Care Med Date: 2017-07-19 Impact factor: 17.440
Authors: Stephen M Pastores; Debra A Goldman; David J Shaz; Natalie Kostelecky; Ryan J Daley; Tim J Peterson; Kay See Tan; Neil A Halpern Journal: Cancer Date: 2018-05-04 Impact factor: 6.860
Authors: S G Oeyen; D D Benoit; L Annemans; P O Depuydt; S J Van Belle; R I Troisi; L A Noens; P Pattyn; J M Decruyenaere Journal: Intensive Care Med Date: 2012-12-18 Impact factor: 17.440
Authors: Dominique M Vandijck; Dominique D Benoit; Pieter O Depuydt; Fritz C Offner; Stijn I Blot; Anna K Van Tilborgh; Joke Nollet; Eva Steel; Lucien A Noens; Johan M Decruyenaere Journal: Intensive Care Med Date: 2008-01-24 Impact factor: 17.440